Orion Corp - Company Profile
Powered by 
All the sales intelligence you need on Orion Corp in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Orion Corp fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Orion Corp.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Orion Corp Catalyst Calendar
Proactively evaluate Orion Corp’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.
A sample of Orion Corp Catalyst Calendar data
| Event Date | Event Type | Company Name | Ticker Symbol | Drug Name | Therapy Area | Indication | Source Type |
|---|---|---|---|---|---|---|---|
| 04 Mar 2020 | GDCTWXYZ | Lorem | Lorem | Lorem | WXYZ | Planned | Lorem |
| 20 Feb 2020 | Phase II/III Trial Initiation | Canary Foundation; CRO TRIDE Asesores SL; Dr. Negrin University Hospital; Leon Research SL; Mario Negri Institute for Pharmacological Research; Negrin Hospital Farmacy; Orion Corp; QBE Europe SA/NV | ORNBV | levosimendan | Cardiovascular | Low Cardiac Output Syndrome | Clinical Trial Registry |
| 10 Dec 2019 | Regulatory Approval (EU) | Orion Corp | ORNBV | darolutamide | Oncology | Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer | GD Estimates |
| 01 Dec 2019 | Phase I/II Trial Completion | Orion Corp | ORNBV | ODM-207 | Oncology | Metastatic Cancer; Solid Tumor | Clinical Trial Registry |
Feature
Catalyst Calendar provides forecasted drug development milestones within the Pharma industry including expected timing, expected outcomes and possible financial impacts.
Benefit
Access:
- Trial Events for trials conducted globally by a company, university, institute or CRO: Trial Initiation, Trial Completion, Trial Results
- Regulatory Events related to drug filings with regulatory bodies, approvals and commercial launches. This is covered for the US, EU and Japan
- Intellectual Property Events for patent and exclusivity expiry specific to the US, EU and Japan: Constraining Patent Expiry (US/EU/Japan), Drug Expiry (US/EU/Japan), Commercial Launch (US/EU/Japan)
Value
Proactively evaluate companies and catalyst impacts
Stay ahead of the competition & improve corporate planning
Bolster business development with timely opportunities
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer